| answer text |
<p>Where a company is willing to set a fair price for a drug, the National Institute
for Health and Care Excellence (NICE) technology appraisal process has been proven
to be suitable for the assessment of drugs for rare diseases. NICE has been able to
recommend a number of drugs for patients with rare diseases through its technology
appraisal programme; recent examples include dinutuximab beta for neuroblastoma and
daratumumab for relapsed and refractory multiple myeloma.</p><p> </p><p>With the aim
of improving the lives of all those affected by a rare disease, the United Kingdom
Government published the UK Strategy for Rare Diseases in 2013, a high-level framework
containing 51 commitments which sets out a seven-year strategic vision (2013-2020).
The Government is committed to implementing the Strategy’s commitments and has, in
January 2018, published Implementation Plans setting out its actions for England.</p>
|
 |
